VUF-11222

CAS No. 1414376-84-3

VUF-11222( —— )

Catalog No. M34735 CAS No. 1414376-84-3

VUF-11222 is a CXCR3 nonmimetic peptide agonist that induces gliosis.VUF 11222 has been used in the study of retinal inflammation.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 148 In Stock
10MG 235 In Stock
25MG 398 In Stock
50MG 576 In Stock
100MG 863 In Stock
200MG 1163 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    VUF-11222
  • Note
    Research use only, not for human use.
  • Brief Description
    VUF-11222 is a CXCR3 nonmimetic peptide agonist that induces gliosis.VUF 11222 has been used in the study of retinal inflammation.
  • Description
    VUF 11222 (Compound 38) is a CXCR3 non-peptide-like agonist. VUF 11222 can be used in the study of inflammation.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Autophagy
  • Target
    CXCR
  • Recptor
    CXCR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1414376-84-3
  • Formula Weight
    552.33
  • Molecular Formula
    C25H31BrIN
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C([N+](CC1=CC=C(C=C1)C2=C(Br)C=CC=C2)(C)C)C=3[C@]4(C(C)(C)[C@](C4)(CC3)[H])[H].[I-]
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Wijtmans M, et al. Chemical subtleties in small-molecule modulation of peptide receptor function: the case of CXCR3 biaryl-type ligands. J Med Chem. 2012 Dec 13;55(23):10572-83.?
molnova catalog
related products
  • CXCR7 antagonist-1

    CXCR7 antagonist-1 is a specific antagonist of the binding of the SDF-1 chemokine or I-TAC to the chemokine receptor CXCR7.

  • AZD8797

    AZD8797 (KAND567) is an orally available, selective and potent human CX3CR1-converting antagonist with inhibitory effects on CX3CR1 and CXCR2.

  • AMD 3465 hexahydrobr...

    AMD 3465 hexahydrobromide is a CXCR4 receptor antagonist with potential anticancer and anti-HIV activity.